Unlocking healthier, longer lives through adult immunization Adult immunization is crucial for longer, healthier, and more productive lives. It offers excellent returns on investment by offsetting costs through significant benefits to individuals, healthcare systems, and society. A new report by the Office of Health Economics (OHE), commissioned by IFPMA, highlights these benefits and was discussed...
Read more
By bringing together health policy and financing, we can create a sustainable future for NCD and mental health responses. The ambition – improving outcomes for people around the world. Last week, the World Health Organization (WHO) and the World Bank brought together health policy and finance stakeholders, including IFPMA and its members, for an International...
Read more
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
Read moreRegulatory alignment across Africa can boost life sciences innovation, aiding pharmaceutical sector growth and enhancing patient access to medicines and vaccines. For over a decade, significant progress has been made in strengthening Africa’s regulatory ecosystem, led by initiatives such as the Africa Medicines Regulatory Harmonization (AMRH), WHO and the African Union Development Agency-NEPAD, paving the...
Read more
IFPMA has partnered with DCVMN to share our industry’s expertise in vaccine development and manufacturing. This presentation illustrates the key stages and timeline to bring vaccines to the market.
Read more
On 1 June, member states represented at the World Health Assembly agreed on amendments to the International Health Regulations (2005), alongside the decision to complete negotiations on a pandemic agreement within a year. The pharmaceutical industry shared its response.
Read moreOn 28 May 2024, IFPMA submitted a statement at the World Health Assembly on Provisional Agenda Item 13.3, Working Group on Amendments to the International Health Regulations (2005). IFPMA acknowledges and appreciates the substantial efforts made by Member States in advancing the text of the Working Group on Amendments to the International Health Regulations (WGIHR)....
Read moreOn 28 May 2024, IFPMA, GSCF, GMTA, DVCMN, and BIO submitted a statement to the World Health Assembly on Provisional Agenda Item 13.4, Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response.
Read moreOn 27 May 2024, IFPMA, IGBA, DITTA, GSCF, WHL, and PATH submitted a constituency statement to the World Health Assembly on Provisional Agenda Item 11.2, NCDs and UHC. IFPMA, IGBA, DITTA, GSCF, WHL, and PATH welcome the agenda item on non-communicable diseases (NCDs) and WHO’s continued commitment to this global health challenge. A life-course approach...
Read moreOn 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 11.8, Antimicrobial resistance. We are broadly supportive of the three strategic priorities described previously and welcome the newly included elevated strategic priority on effective governance and financing, which also recognizes the important role of all stakeholders, including the...
Read moreOn 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 15.4, Climate change and health. IFPMA commends the Resolution and the recognition of climate change as an urgent global challenge. Innovative pharmaceutical companies are setting ambitious, science-aligned targets and investing to develop environmentally sustainable products, manufacturing processes, and...
Read more